Exponent, Inc. (EXPO) Stock Price & Analysis
Exponent, Inc. (EXPO) closed at USD 77.43 on Friday, October 23, 2026, up 0.41% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 77.11; the Oct 23, 2026 session ranged USD 75.7–77.69 on volume of 377,589 shares. Market capitalization is $3.68B, with a 52-week range of USD 51.91–81.95 (NMS). Source: Nexqual, retrieved October 24, 2026 at 14:54 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EXPO.md
Key facts (EXPO)
- Last four reported quarters (through Jul 3, 2026): revenue $632M, net income $112M (17.7% margin), free cash flow $109M (SEC filings).
- Valuation: P/E 32.9x (avg 41.1x at the last 3 fiscal year-ends).
- Insider open-market sales, last ~7 months: 9 Form 4 filings, $1.7M; 4 not under a Rule 10b5-1 plan ($491K); 1 by opportunistic insiders (1 outside 10b5-1 plans), 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 84 (range 72–90).
- Total return with dividends: 1Y +13.7% vs S&P 500 +13.4%; 5Y -28.1% vs S&P 500 +76.9%.
- Next earnings: 2026-10-29, EPS estimate USD 0.62, revenue estimate $153M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (EXPO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $466M | $513M | $537M | $559M | $582M | $632M |
| Operating income | $109M | $141M | $111M | $120M | $120M | $128M |
| Net income | $101M | $102M | $100M | $109M | $106M | $112M |
| EPS (diluted) | $1.90 | $1.96 | $1.94 | $2.11 | $2.07 | — |
| Free cash flow | $118M | $81.8M | $111M | $138M | $122M | $109M |
| Operating margin | 23.4% | 27.4% | 20.7% | 21.4% | 20.6% | 20.2% |
| Net margin | 21.7% | 19.9% | 18.7% | 19.5% | 18.2% | 17.7% |
| Revenue growth | +16.6% | +10.1% | +4.6% | +4.1% | +4.2% | — |
| Cash + short-term investments | — | — | $187M | $259M | $222M | — |
Fiscal years end Jan. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 3, 2026) (EXPO)
P/E 32.9x · P/S 5.8x · P/FCF 33.9x · P/B 12.8x · FCF yield 2.95% · Earnings yield 3.04% · Dividend yield (paid, TTM) 1.67% · Buyback yield (TTM) 5.72%
P/E at fiscal year-ends: Jan 2026 34.7x, Jan 2025 43.4x, Dec 2023 45.3x.
Insider sales (SEC Form 4, open-market, last ~7 months) (EXPO)
5 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Corrigan Catherine | Chief Executive Officer | 1,707 | $113K | 1.3% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-15 | Corrigan Catherine | Chief Executive Officer | 1,737 | $109K | 1.5% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-15 | Corrigan Catherine | President & CEO | 4,119 | $235K | 3.7% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-26 | James Bradley A | Group Vice President | 2,000 | $115K | 64.4% | No | Routine (sold in May each year 2023–2025) |
| 2026-05-19 | Reiss Richard | Group Vice President | 1,672 | $98K | 42.2% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-15 | Corrigan Catherine | President & CEO | 4,194 | $227K | 3.8% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-13 | Rakow Joseph | Group Vice President | 2,945 | $161K | 100% | No | Routine (sold in May each year 2023–2025) |
| 2026-05-13 | Sala Joseph | Group Vice President | 2,066 | $117K | 100% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-03-16…2026-04-15 | Corrigan Catherine | President & CEO | 7,821 | $529K | 7% | Yes | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (EXPO)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 84 (low 72, high 90).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-31 | UBS | Target lowered | Neutral | $75 → $72 |
| 2026-07-31 | JP Morgan | Target raised | Overweight | $80 → $90 |
Total return (dividends reinvested) (EXPO)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +13.7% | -28.1% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +13.8% | -6.4% |
| Volatility (annualized) | 33.0% | 31.6% |
| Max drawdown | -32.5% (Feb 2026→May 2026) | -54.6% (Nov 2021→May 2026) |
EXPO revenue by business segment (quarter ended Jul 3, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Engineering & Other Scientific | $148.8M | 86.7% | +23.0% |
| Environmental & Health | $22.8M | 13.3% | +8.6% |
| Total revenue | $171.6M | 100% | — |
EXPO revenue by region (fiscal year ended Jan 2, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $520.6M | 89.4% | +5.6% |
| Non Us | $61.4M | 10.6% | -6.1% |
| Total revenue | $582.0M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
EXPO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.62 | $0.64 | -2.6% | $153.4M | 4 |
| Next quarter (ends Dec 2026) | $0.54 | $0.58 | -7.8% | $145.2M | 4 |
| Current fiscal year (ends Dec 2026) | $2.41 | $2.47 | -2.4% | $612.1M | 4 |
| Next fiscal year (ends Dec 2027) | $2.72 | $2.76 | -1.4% | $663.9M | 4 |
EXPO options: expected move
Options price a move of about ±9.5% (±$7.38) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±4.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 27 | 42.4% | ±9.5% |
| Dec 18, 2026 | 55 | 38.0% | ±12.0% |
| Mar 19, 2027 | 146 | 35.8% | ±18.0% |
| Jun 17, 2027 | 236 | 35.5% | ±22.4% |
30-day implied volatility 35.3% vs 32.3% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 24, 2026 at 14:54 UTC)
| Price | USD 77.43 |
|---|---|
| Change | ▲ 0.41% (up) |
| Previous Close | USD 77.11 |
| Open | USD 76.36 |
| Day Range | USD 75.7 – 77.69 |
| 52-Week Range | USD 51.91 – 81.95 |
| Volume | 377,589 shares |
| Market Cap | $3.68B |
| Exchange | NMS |
Technical Analysis (EXPO)
Nexqual's technical model rates EXPO "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 24, 2026 at 14:54 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 77.25 (overbought) |
| vs SMA50 | Above (USD 69.2) |
| MACD | 2.08 (positive) |
Analyst Ratings (EXPO)
Wall Street analysts rate EXPO "Buy" based on 4 analysts, with a mean price target of USD 84 (range USD 72–90), per Nexqual as of October 24, 2026 at 14:54 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 84 |
| High Target | USD 90 |
| Low Target | USD 72 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (EXPO)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 0.62 |
| Revenue Estimate | $153.43M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.6 vs est 0.6 ▲ beat |
| 2026-03-31 | USD 0.59 vs est 0.61 ▼ miss |
| 2025-12-31 | USD 0.49 vs est 0.47 ▲ beat |
| 2025-09-30 | USD 0.55 vs est 0.53 ▲ beat |
Source: Nexqual, October 24, 2026 at 14:54 UTC.
Financials & Fundamentals (EXPO)
| Total Revenue | $567.13M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +12.00% |
| Gross Margin | +36.42% |
| Operating Margin | +18.82% |
| Profit Margin | +19.71% |
| ROE | +31.20% |
| Debt / Equity | 0.28 |
| Current Ratio | 1.98 |
| Total Cash | $66.63M |
| Total Debt | $80.72M |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | $108.56M (17.2% of revenue) |
Source: Nexqual, October 24, 2026 at 14:54 UTC.
Financial Health Score (EXPO)
Nexqual rates Exponent, Inc.'s overall financial health "Solid" across five dimensions, as of October 24, 2026 at 14:54 UTC.
| Growth | Mixed — Revenue +3.5% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 36%, operating 19% (last 12 months) |
| Balance Sheet | Strong — $67M cash vs $81M debt |
| Cash Flow | Strong — FCF $109M (last 4 quarters to Jul 2026, SEC), 17% margin |
| Efficiency | Strong — ROE 31%, ROA 11.3% |
Ownership (EXPO)
| Insider Ownership | +1.24% |
|---|---|
| Institutional Ownership | +101.04% |
| Shares Outstanding | 47.55M |
| Float | 46.90M |
| Short % of Float | +7.62% |
Source: Nexqual, October 24, 2026 at 14:54 UTC.
Leadership (EXPO)
Exponent, Inc. is led by Catherine Ford Corrigan P.E., CEO & Director, per Nexqual as of October 24, 2026 at 14:54 UTC.
| CEO & Director | Catherine Ford Corrigan P.E. |
|---|---|
| Executive VP, Corporate Secretary & Director | Richard L. Schlenker |
| Group Vice President | Maureen T. F. Reitman F.S.P.E., P.E., Sc.D. |
| Group Vice President | Joseph Rakow |
| Group Vice President | Joseph Sala |
Major Backers & Investors (EXPO)
Notable institutional backers of Exponent, Inc. include Kayne Anderson Rudnick Investment Management LLC, Geneva Capital Management LLC, Royce & Associates LP, according to Nexqual as of October 24, 2026 at 14:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kayne Anderson Rudnick Investment Management LLC | 8.4% |
| Geneva Capital Management LLC | 2.96% |
| Royce & Associates LP | 2.78% |
| Conestoga Capital Advisors, LLC | 2.66% |
| Morgan Stanley | 2.55% |
| First TRT Exch-Trd Fd. VI-First TRT SMID Cap Rising Dividend Achievers | 2.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.01% |
| Vanguard Group | 11.2% |
| State Street | 4.09% |
| Geode Capital | 3.68% |
Source: Nexqual, October 24, 2026 at 14:54 UTC.
From Exponent, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Our expertise enables us to comprehend and evaluate the interaction between the human body as a biological system and the physical environment.
- Our collective expertise allows us to deliver clear, comprehensive, scientifically grounded insights that enable clients to make informed, defensible, and data‑driven decisions regarding human health risks.
Partnerships
- The history of Exponent, Inc. goes back to 1967, with the founding of the partnership Failure Analysis Associates, which was incorporated the following year in California and reincorporated in Delaware as Failure Analysis Associates, Inc. in 1988.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business can be adversely impacted by regulatory uncertainty, deregulation or reduced regulatory enforcement.
- Laws regarding data protection continue to rapidly evolve, and failure to protect client and employee data may have an adverse effect on our business.
- Our adoption and use of artificial intelligence technologies may create operational, legal, and regulatory risks.
- Failure to comply with domestic and international export laws could adversely affect our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TPC | Tutor Perini Corporation | USD 76.86 | ▼ 0.03% |
| AGX | Argan, Inc. | USD 331.03 | ▲ 0.22% |
| ROAD | Construction Partners, Inc. | USD 83.04 | ▼ 1.06% |
| GVA | Granite Construction Incorporat | USD 106.45 | ▼ 0.93% |
| ECG | Everus Construction Group, Inc. | USD 94.91 | ▼ 2.21% |
| KBR | KBR, Inc. | USD 39.23 | ▼ 0.76% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 14:54 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt